Neurofilament light (NFL) is a powerful and sensitive biomarker for tracking neuronal health and disease progression.
J.P. Morgan analyst Casey Woodring maintained a Hold rating on Charles River Labs (CRL – Research Report) yesterday and set a price target of ...
The stock's fall snapped a two-day winning streak.
As promised, the restructuring initiatives taking place at Charles River Labs (NYSE: CRL) have resulted in a reduced ...
Q4 2024 Earnings Call Transcript February 19, 2025 Charles River Laboratories International, Inc. beats earnings expectations ...
Barclays lowered the firm’s price target on Charles River (CRL) to $160 from $166 and keeps an Equal Weight rating on the shares post the Q4 ...
Todd Spencer; Vice President, Investor Relations; Charles River Laboratories International Inc James Foster; Chairman of the Board, President, Chief Executive Officer; Charles River Laboratories ...
A lower court properly threw out a securities suit alleging Charles River Laboratories International Inc. misrepresented its ...
Charles River's balance sheet is sound, with its revenue cyclicality and operating leverage each possessing a medium rating. The company ended 2024 with about $195 million in cash, and it recorded a ...
Charles River Laboratories International, Inc. has reported its fourth-quarter and full-year 2024 results and provided ...
Charles River Laboratories International Inc (NYSE:CRL) reported fourth-quarter 2024 revenue of $1 billion, a decrease of 1.1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results